Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Capital Expenditures (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Capital Expenditures for 15 consecutive years, with $700000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures rose 975.0% to $700000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $744000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $744000.0 for FY2025, N/A changed from the prior year.
  • Capital Expenditures hit $700000.0 in Q4 2025 for Cardiff Oncology, up from $18000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $902000.0 in Q1 2025 to a low of -$876000.0 in Q2 2025.
  • Historically, Capital Expenditures has averaged $92000.0 across 5 years, with a median of $71000.0 in 2021.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 1055.56% in 2022 and later plummeted 1100.0% in 2024.
  • Year by year, Capital Expenditures stood at -$92000.0 in 2021, then tumbled by 659.78% to -$699000.0 in 2022, then surged by 101.14% to $8000.0 in 2023, then tumbled by 1100.0% to -$80000.0 in 2024, then skyrocketed by 975.0% to $700000.0 in 2025.
  • Business Quant data shows Capital Expenditures for CRDF at $700000.0 in Q4 2025, $18000.0 in Q3 2025, and -$876000.0 in Q2 2025.